About Us
We are a leading clinical-stage biotechnology company pioneering the research and development of first-in-class lentiviral vector-based vaccine candidates for the prevention and treatment of cancers and chronic infectious diseases.
WHAT WE DO
At TheraVectys, we are working to cure and prevent cancers and major infectious diseases.
To fight cancer and diseases such as AIDS, malaria and tuberculosis, efficient cytotoxic T cells, which directly kill infected or tumor cells are required. However, current vaccines and vaccine-candidates fail to achieve the desired result.
Our proprietary lentiviral vector immunotherapy induces unprecedented, high-quality T cell and antibody responses, creating strong and long-term protective or therapeutic immunity.
With many applications, we have an indisputable medicinal path able to save millions of lives.
HOW WE ARE DIFFERENT
Our modified lentiviral vectors have unparalleled properties:
- Non-integrative vectors: Viral DNA does not integrate into the host cell DNA, unlike retroviral vectors.
- DNA flap technology: Enables the virus to cross the nucleus membrane so that genes can be transferred into non-dividing cells.
- Dendritic cell targeting: To elicit a strong, long-standing T cell and antibody-mediated immune response.
WHO WE ARE
TheraVectys is the first company globally to pioneer the clinical translation of lentiviral vector technology through direct in vivo vaccine injection in humans, marking a critical paradigm shift from traditional ex vivo cell therapies to direct in vivo therapeutic and prophylactic applications.
Our development activities are centered on our proprietary lentiviral vector-based vaccination platform, which is designed to elicit robust cellular immune responses capable of overcoming immune tolerance while supporting sustained immune activation.
The modular and adaptable architecture of our platform enables both integrative and non-integrative designs, supporting the incorporation of different antigen constructs to achieve controlled, effective antigen expression and enabling the scalable expansion of our pipeline across a diversified range of disease indications..